J
Jin Xu
Researcher at Fudan University
Publications - 189
Citations - 7337
Jin Xu is an academic researcher from Fudan University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 40, co-authored 156 publications receiving 4575 citations. Previous affiliations of Jin Xu include Fudan University Shanghai Medical College.
Papers
More filters
Journal ArticleDOI
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
TL;DR: This review summarizes knowledge of the reciprocal interaction between antitumor immunity and distinct cell death mechanisms, particularly necroptosis, ferroPTosis, and pyroaptosis, which are the three potentially novel mechanisms of immunogenic cell death.
Journal ArticleDOI
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Xiaoqi Mao,Jin Xu,Wei Wang,Chen Liang,Jie Hua,Jiang Liu,Bo Zhang,Qingcai Meng,Xianjun Yu,Si Shi +9 more
TL;DR: Cancer-associated fibroblasts (CAFs), a stromal cell population with cell-of-origin, phenotypic and functional heterogeneity, are the most essential components of the tumor microenvironment (TME). Through multiple pathways, activated CAFs can promote tumor growth, angiogenesis, invasion and metastasis, along with extracellular matrix remodeling and even chemoresistance.
Journal ArticleDOI
Carbon nanotubes in cancer diagnosis and therapy
Shunrong Ji,Chen Liu,Bo Zhang,Feng Yang,Jin Xu,Jiang Long,Chen Jin,De Liang Fu,Quan Xing Ni,Xianjun Yu +9 more
TL;DR: This review will show how carbon nanotubes have been introduced into the diagnosis and treatment of cancer, and novel SWNT-based tumor-targeted drug delivery systems (DDS) will be highlighted.
Journal ArticleDOI
LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Guopei Luo,Xianjun Yu,Chen Jin,Feng Yang,Deliang Fu,Jiang Long,Jin Xu,Changyou Zhan,Weiyue Lu +8 more
TL;DR: This study indicates that LyP-1-NP is a promising carrier for target-specific drug delivery to lymphatic metastatic tumors.
Journal ArticleDOI
The microbiota and microbiome in pancreatic cancer: more influential than expected.
Miao Yan Wei,Si Shi,Chen Liang,Qing Cai Meng,Jie Hua,Yi Yin Zhang,Jiang Liu,Bo Zhang,Jin Xu,Xianjun Yu +9 more
TL;DR: A better understanding of the microbiota in PDAC might lead to the establishment of screening or early-stage diagnosis methods, implementation of cancer bacteriotherapy, adjustment of therapeutic efficacy even alleviating the adverse effects, creating new opportunities and fostering hope for desperate PDAC patients.